The Time to Step Up Is Now: Advocating for 340B

SPONSORED CONTENT

Pop Quiz: Which of these statements are false?

  1. The United States spends more on health care than any other developed nation. But when compared to 11 other high-income countries, the U.S. ranks last for access to care, health equity, and health outcomes. Case in point: Despite significant advances in HIV prevention and treatment in the last 40 years,
Read More »

Arkansas’ Novel 340B Contract Pharmacy Law Doesn’t Conflict with Federal Law, State Officials Tell Court

Arkansas Insurance Department
The Arkansas insurance commissioner and 340B covered entities told a federal district judge that a state law requiring drug makers to honor 340B contract pharmacy arrangements does not conflict with federal laws.

Arkansas’s first-of-its-kind law requiring drug makers to honor 340B pricing when covered entities use contract pharmacies to dispense 340B drugs is not preempted by the federal 340B statute since the state law applies only to the acquisition and

Read More »

Maximizing 340B Program Value with Specialty Medication Access

SPONSORED CONTENT

At AllianceRx Walgreens Pharmacy, each covered entity we meet with describes circumstances unique to its hospital, patients, and pharmacy arrangements. The common element for all is the increasing complexity of 340B programming – often changing by the day. Other themes we often hear about include variable patient volumes, unpredictable cost trends and operational

Read More »

NACHC Hopes Congress Will Pass Laws Protecting 340B Providers This Year

NACHC “would love to see” Congress pass legislation by the end of this year protecting health centers from drug manufacturers and PBMs' restrictions on 340B access, NACHC Senior Vice President Joe Dunn said during a news conference yesterday.

The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered

Read More »

News Alert

25 States File Joint Briefs Backing HHS and HRSA in 340B Contract Pharmacy Cases

Connecticut Attorney General William Tong (D) led the coalition of states backing the federal government in 340B contract pharmacy cases before federal appeals courts.

Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber

Read More »

340B Providers Lose their Biggest GOP Ally in U.S. House

U.S. Rep. David McKinley (R-W.Va.) lost his GOP primary election this week. It's a huge blow for 340B entities that have relied on his help in Congress for years.

In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in

Read More »

Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Please

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.

Please Login or Become a Paid

Read More »

340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds

Avalere Health says it found that 340B DSH hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.

Read More »

JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly

New research in JAMA Internal Medicine says many NCI-designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially." 340B groups point out that the rates are negotiated and they need the revenue for their safety net mission.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report